down arrow

Passage Bio, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US7027121000
USD
9.18
1.15 (14.36%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

8.259.18

52 Week

5.1220.20
Valuation
Technical
Day's Volume

CASH

81.02 k

Shareholding (Mar 2025)

FII

19.43%

Held by 17 FIIs

DII

49.85%

Held by 10 DIIs

Promoter

25.03%

How big is Passage Bio, Inc.?

22-Jun-2025

As of Jun 18, Passage Bio, Inc. has a market capitalization of 23.65 million and reported net sales of 0.00 million with a net profit of -63.45 million for the latest four quarters. As of Dec 24, shareholder's funds were 61.26 million and total assets were 102.41 million.

As of Jun 18, Passage Bio, Inc. has a market capitalization of 23.65 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 0.00 million, while the sum of net profit for the same period is -63.45 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds at 61.26 million and total assets at 102.41 million.

Read More

What does Passage Bio, Inc. do?

22-Jun-2025

Passage Bio, Inc. is a preclinical stage genetic medicines company focused on developing therapies for rare, monogenic central nervous system diseases. It has a market cap of $23.65 million and reported a net profit loss of $15 million as of March 2025.

Overview: <BR>Passage Bio, Inc. is a preclinical stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) diseases within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -15 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 23.65 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.28 <BR>Return on Equity: -119.02% <BR>Price to Book: 0.51<BR><BR>Contact Details: <BR>Address: TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR PHILADELPHIA PA : 19103 <BR>Tel: 1 267 8660312 <BR>Fax: 1 302 6555049 <BR>Website: https://www.passagebio.com/

Read More

Who are in the management team of Passage Bio, Inc.?

22-Jun-2025

As of March 2022, the management team of Passage Bio, Inc. includes Dr. Tadataka Yamada (Independent Chairman), Dr. Bruce Goldsmith (CEO), Dr. Stephen Squinto (Acting Head of R&D), and several independent directors, bringing diverse expertise to the biotechnology sector.

As of March 2022, the management team of Passage Bio, Inc. includes the following individuals:<BR><BR>- Dr. Tadataka Yamada, Independent Chairman of the Board<BR>- Dr. Bruce Goldsmith, President, Chief Executive Officer, and Director<BR>- Dr. Stephen Squinto, Acting Head of Research and Development and Director<BR>- Dr. Athena Countouriotis, Independent Director<BR>- Mr. Patrick Heron, Independent Director<BR>- Mr. Saqib Islam, Independent Director<BR>- Mr. Sandip Kapadia, Independent Director<BR>- Dr. Liam Ratcliffe, Independent Director<BR><BR>This team brings a diverse range of expertise to the company, supporting its mission in the biotechnology sector.

Read More

Is Passage Bio, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Passage Bio, Inc. shows a mildly bullish trend overall, with mixed technical indicators and recent performance outperforming the S&P 500, but it has significantly negative long-term returns.

As of 8 September 2025, the technical trend for Passage Bio, Inc. has changed from bullish to mildly bullish. The MACD indicates a mildly bullish stance on both the weekly and monthly time frames, while the Dow Theory shows a mildly bullish signal on the weekly chart. However, the moving averages are mildly bearish on the daily time frame, and the KST and OBV are bearish or showing no trend, respectively, on the weekly and monthly charts. <BR><BR>In terms of performance, the stock has returned 8.32% over the past week and 4.57% over the past month, outperforming the S&P 500, which returned 1.05% and 2.33% in the same periods. However, the longer-term returns are significantly negative, with a year-to-date return of -33.43% compared to the S&P 500's 12.22%, and a one-year return of -46.15% against the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, but the strength is tempered by mixed signals across different indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 22 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.41

stock-summary
Return on Equity

-129.18%

stock-summary
Price to Book

0.56

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-9 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
28.88%
0%
28.88%
6 Months
-7.99%
0%
-7.99%
1 Year
-48.41%
0%
-48.41%
2 Years
-31.16%
0%
-31.16%
3 Years
652.7%
0%
652.7%
4 Years
-93.61%
0%
-93.61%
5 Years
-98.09%
0%
-98.09%

Passage Bio, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Passage Bio, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Passage Bio, Inc. has changed from bullish to mildly bullish. The MACD indicates a mildly bullish stance on both the weekly and monthly time frames, while the Dow Theory shows a mildly bullish signal on the weekly chart. However, the moving averages are mildly bearish on the daily time frame, and the KST and OBV are bearish or showing no trend, respectively, on the weekly and monthly charts. In terms of performance, the stock has returned 8.32% over the past week and 4.57% over the past month, outperforming the S&P 500, which returned 1.05% and 2.33% in the same periods. However, the longer-term returns are significantly negative, with a year-to-date return of -33.43% compared to the S&P 500's 12.22%, and a one-year return of -46.15% against the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, but the strength is tempered by mixed s...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
3.33%
EBIT to Interest (avg)
-117.34
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.28
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
76.88%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.56
EV to EBIT
0.55
EV to EBITDA
0.57
EV to Capital Employed
2.57
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
468.40%
ROE (Latest)
-119.02%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 6 Schemes (5.68%)

Foreign Institutions

Held by 17 Foreign Institutions (19.43%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 41.25% vs 33.05% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.10",
          "val2": "-16.10",
          "chgp": "37.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.40",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.40",
          "val2": "-16.00",
          "chgp": "41.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 36.53% vs 24.98% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-62.10",
          "val2": "-96.40",
          "chgp": "35.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-5.20",
          "val2": "-7.80",
          "chgp": "33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-64.80",
          "val2": "-102.10",
          "chgp": "36.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-10.10
-16.10
37.27%
Interest
0.00
0.00
Exceptional Items
0.00
-0.40
100.00%
Consolidate Net Profit
-9.40
-16.00
41.25%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 41.25% vs 33.05% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-62.10
-96.40
35.58%
Interest
0.00
0.00
Exceptional Items
-5.20
-7.80
33.33%
Consolidate Net Profit
-64.80
-102.10
36.53%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 36.53% vs 24.98% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Passage Bio, Inc. stock-summary
stock-summary
Passage Bio, Inc.
Pharmaceuticals & Biotechnology
Passage Bio Inc is a preclinical stage genetic medicines company. The Company is focused on developing transformative therapies for rare, monogenic central nervous system (CNS). The Company is developing a portfolio of six life transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The Company's products pipeline includes PBGM01 for the treatment of gangliosidosis (GM1), PBFT02 for the treatment of frontotemporal dementia (FTD), and PBKR03 for the treatment of Krabbe disease. The Company’s products PBGM01, utilizes an AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal beta-galactosidase (beta-gal), PBFT02, utilizes an AAV1 capsid to deliver to the brain a functional GRN gene encoding progranulin (PGRN), and PBKR03, utilizes an AAVhu68 capsid to deliver to the brain and peripheral tissues a functional gene encoding the hydrolytic enzyme galactosylceramidase (GALC).
Company Coordinates stock-summary
Company Details
TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR PHILADELPHIA PA : 19103
stock-summary
Tel: 1 267 8660312
stock-summary
https://www.passagebio.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."